Abstract

The venture arms of Pfizer and Roche have led a $43 million round of financing for Second Genome, which is developing small molecules that modulate the microbiome. Second Genome plans to use the ca...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call